TOMI Environmental Solutions Appoints Total Clean Air as Preferred European Partner for SteraMist iHP Decontamination Technology
Rhea-AI Summary
TOMI Environmental Solutions (NASDAQ: TOMZ) appointed Total Clean Air as its Preferred European Partner for SteraMist iHP, making TCA the primary provider for sales, service, and technical support across the UK and EU. The agreement adds in-region validation, consignment stock, a UK showroom, and a dedicated workshop to support GMP Annex 1 compliance and surge demand in life sciences.
Market context includes a UK infection control market projected to exceed $6 billion by 2031 and a UK sterility testing market forecast at a 14% CAGR through 2035.
Positive
- TCA designated Preferred European Partner for SteraMist iHP
- UK infection control market projected to exceed $6 billion by 2031
- UK sterility testing market projected 14% CAGR through 2035
- TCA will hold consignment stock and dedicated workshop support
- In-region technical support and validation services for GMP Annex 1
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
TOMZ was down 8.72% while 4 momentum-screened peers (e.g., CLWT, DEVS, CLIR) showed gains of about 3–5%. With 0 peers moving in the same direction, the move appears stock-specific rather than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 23 | Regulatory approvals | Positive | +12.7% | Biocidal product authorizations for BIT and SteraMist iHP in GB and NI. |
| Jan 20 | Contract win | Positive | +0.6% | Custom Engineered System sale integrating SteraMist iHP into TCA platform. |
| Jan 06 | System installation | Positive | -3.0% | SteraMist Hybrid System installed at research university sterilization facility. |
| Dec 22 | Sector expansion | Positive | +1.4% | Multi-stage SteraMist iHP rollout at cell and gene therapy site. |
| Dec 18 | Large purchase order | Positive | -0.1% | Approx. <b>$500,000</b> SteraMist iHP integration order from biopharma leader. |
Recent SteraMist-related wins and approvals generally saw modestly positive reactions, but there is a mix of aligned moves and occasional selloffs on good news.
Over the past several months, TOMZ has reported multiple SteraMist iHP wins and regulatory milestones, including UK and Northern Ireland biocidal approvals on Feb 23, 2026 and several sizable integrations into pharmaceutical and cell and gene therapy facilities. Price reactions ranged from -2.97% to 12.7%, showing that even clearly positive commercial updates can draw mixed trading responses. Today’s broader European partnership with Total Clean Air continues this commercialization theme in regulated life sciences markets.
Regulatory & Risk Context
An effective S-3 shelf filed on 2025-11-14 allows TOMZ to register and potentially issue up to $50,000,000 of various securities over its term. As of the provided data, usage_count is 0, indicating no takedowns recorded from this shelf in the supplied filings.
Market Pulse Summary
This announcement expands TOMZ’s European reach by making Total Clean Air its Preferred European Partner for SteraMist iHP, targeting a UK infection control market projected to exceed $6 billion by 2031 and a sterility-testing segment growing at 14% CAGR through 2035. It reinforces a pattern of commercial wins following prior SteraMist deployments and approvals. Investors may monitor how this partnership converts into orders, progress on Nasdaq compliance, and any utilization of the $50,000,000 S-3 shelf.
Key Terms
gmp annex 1 regulatory
mhra regulatory
AI-generated analysis. Not financial advice.
Strategic Partnership Strengthens UK and EU GMP Annex 1 Compliance
FREDERICK, Md., March 03, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, and Total Clean Air (“TCA”), a leading United Kingdom cleanroom design, build, and validation specialist, today announced a strategic partnership agreement establishing TCA as TOMI's Preferred European Partner for its industry-leading SteraMist iHP decontamination technology.
Under this new agreement, TCA becomes the primary partner for sales, service, and technical support across the United Kingdom and the European Union. This collaboration creates a streamlined infrastructure to meet surging demand for aseptic processing and high-level decontamination in the life sciences, pharmaceutical, and controlled environment sectors—markets in the UK alone projected to exceed
“We are pleased to appoint Total Clean Air as our Preferred European Partner,” said Elissa J. (E.J.) Shane, Chief Operating Officer of TOMI. “Their deep technical proficiency in controlled environments perfectly complements the speed and efficacy of our innovative SteraMist iHP technology. Together, we are setting a new benchmark for automated and mobile decontamination across the European life sciences sector, providing customers with unparalleled local support and validated results.”
The partnership launches at a critical time as the UK sterility testing market is projected to grow at a
TCA will maintain consignment stock of SteraMist iHP equipment and consumables, supported by a dedicated workshop facility. TCA will provide annual calibration, routine inspections, and validation support—capabilities essential to a sustainable, high-quality European service model. Building upon the longstanding footprint of TCA in the UK and EU markets, their current customer base is increasingly interested in innovative decontamination solutions to meet evolving safety standards.
Phillip Godden, Chief Executive Officer of Total Clean Air, added: “We are proud to represent TOMI as their Preferred European Partner. SteraMist iHP is a transformative decontamination solution for the pharmaceutical and life sciences industries. By merging our established service infrastructure and partnerships with TOMI’s world-class technology, we provide a turnkey solution that addresses GMP Annex 1 compliance and the most rigorous decontamination challenges in Europe.”
A key feature of the partnership is a new demonstration and trial program. SteraMist equipment will be hosted at TCA’s UK showroom based in Street, Somerset, for hands-on evaluation and can be readily deployed to customer sites across Europe, servicing a diverse range of end-users including Pharma and Biotech companies, medical device manufacturers, and microbial testing laboratories.
About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®
TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas.
TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences.
TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association.
For additional information, please visit https://www.steramist.com or contact us at info@tomimist.com.
About Total Clean Air Limited
Total Clean Air Limited is a UK-based clean air and controlled environments specialist, delivering design, build, validation, and lifecycle support for cleanrooms, containment laboratories, and critical ventilation systems. Operating across pharmaceutical, life sciences, healthcare, and advanced manufacturing sectors, Total Clean Air is recognised for its engineering-led approach, UKAS-accredited validation capability, and strong ‘We Care’ culture underpinning long-term client partnerships.
Forward-Looking Statements
This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements regarding expansion of UK and international markets and ability to achieve revenue growth. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to acquire new customers and expands sales; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.
INVESTOR RELATIONS CONTACT:
John Nesbett/Rosalyn Christian
IMS Investor Relations
tomi@imsinvestorrelations.com
FAQ
What did TOMI (TOMZ) announce on March 3, 2026 about European distribution?
How does the TOMI–TCA partnership affect GMP Annex 1 compliance for European customers?
Will Total Clean Air stock SteraMist equipment and consumables for TOMI (TOMZ)?
Where can European customers see and trial SteraMist iHP under the TOMI partnership?
What market opportunity did TOMI highlight for SteraMist iHP in the UK and Europe?
How will the TOMI and TCA collaboration support life sciences customers using SteraMist?
